Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification.

Kampstra ASB, Dekkers JS, Volkov M, Dorjée AL, Hafkenscheid L, Kempers AC, van Delft M, Kissel T, Reijm S, Janssen GMC, van Veelen PA, Bang H, Huizinga TWJ, Trouw LA, van der Woude D, Toes REM.

Ann Rheum Dis. 2019 Jul;78(7):908-916. doi: 10.1136/annrheumdis-2018-214950. Epub 2019 May 31.

PMID:
31151934
2.

Autoantibody status is not associated with early treatment response to first-line methotrexate in patients with early rheumatoid arthritis.

Dekkers JS, Bergstra SA, Chopra A, Tikly M, Fonseca JE, Salomon-Escoto K, Huizinga TWJ, van der Woude D.

Rheumatology (Oxford). 2019 Jan 1;58(1):149-153. doi: 10.1093/rheumatology/key263.

PMID:
30204896
3.

Breach of autoreactive B cell tolerance by post-translationally modified proteins.

Dekkers JS, Verheul MK, Stoop JN, Liu B, Ioan-Facsinay A, van Veelen PA, de Ru AH, Janssen GMC, Hegen M, Rapecki S, Huizinga TWJ, Trouw LA, Toes REM.

Ann Rheum Dis. 2017 Aug;76(8):1449-1457. doi: 10.1136/annrheumdis-2016-210772. Epub 2017 Apr 25.

PMID:
28442530
4.

Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis.

Dekkers JS, Schoones JW, Huizinga TW, Toes RE, van der Helm-van Mil AH.

Ann Rheum Dis. 2017 Feb;76(2):458-467. doi: 10.1136/annrheumdis-2016-209830. Epub 2016 Aug 1. Review.

PMID:
27481831

Supplemental Content

Loading ...
Support Center